[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.179.146. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 15, 1995

HLA Typing for Bone Marrow TransplantationNew Polymerase Chain Reaction—Based Methods

Author Affiliations

From the Department of Human Genetics, Roche Molecular Systems Inc, Alameda, Calif. The PCR process is covered by issued and pending patents owned by Hoffmann-La Roche Inc and F. Hoffman-La Roche Ltd.

JAMA. 1995;273(7):586-591. doi:10.1001/jama.1995.03520310084034
Abstract

BONE MARROW transplantation, first introduced into clinical practice in the 1960s, has now become an accepted form of therapy for a variety of hematologic malignancies as well as a number of other cancers, inherited blood disorders, immunodeficiency syndromes, and certain metabolic diseases.1,2 In general, the purpose of bone marrow transplantation is to (1) replace malignant or genetically defective hematopoietic stem cells with healthy, fully functional stem cells; (2) allow the cancer patient to survive the high-dose radiation and/or chemotherapy required to destroy the malignant cells; and (3) in the case of certain cancers, provide a source of immunocompetent cells that can destroy any residual malignant cells (graft vs leukemia effect).3-5 The clinical procedure of bone marrow transplantation involves the destruction of the patient's own marrow by irradiation and/or chemotherapy followed by the infusion of healthy bone marrow obtained from another individual (an allogeneic transplant). In cases of solid

First Page Preview View Large
First page PDF preview
First page PDF preview
×